MolDX: NRAS Genetic Testing

Noridian covers somatic NRAS genetic testing of tumor tissue only for metastatic colorectal cancer per NCCN Clinical Practice Guidelines (Version 2.2016), as part of RAS/BRAF genotyping to guide anti‑EGFR therapy decisions. All other NRAS testing—including testing for other tumor types (eg, melanoma, leukemia, bladder, liver, thyroid) and germline NRAS testing for Noonan syndrome or other RASopathies—is non‑covered due to insufficient evidence of clinical utility.

"Somatic NRAS mutation testing of tumor tissue is covered for patients with metastatic colorectal cancer in accordance with NCCN Clinical Practice Guidelines (Version 2."

Sign up to see full coverage criteria, indications, and limitations.